Press Release: Basilea reports on portfolio -2-

References

1. ERADICATE study: Clinicaltrials.gov identifier NCT03138733K. Hamed,

M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in

Staphylococcus aureus bacteremia: a novel protocol for a double-blind,

Phase III trial. Future Microbiology. 2020 (1), 35-48

2. Basilea in-licensed derazantinib from ArQule Inc., a wholly-owned

subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

3. Isavuconazole phase 3 study conducted by Asahi Kasei Pharma:

Clinicaltrials.gov identifier NCT03471988

4. IQVIA, September 2021. In-market sales reported as moving annual total

(MAT) in U.S. dollar.

5. FIDES-01 study: Clinicaltrials.gov identifier NCT03230318

6. FIDES-02 study: Clinicaltrials.gov identifier NCT04045613

7. FIDES-03 study: ClinicalTrials.gov identifier NCT04604132

8. Biomarker-driven phase 2 study with lisavanbulin: ClinicalTrials.gov

identifier NCT02490800

9. Lisavanbulin phase 1 study conducted in collaboration with the ABTC:

ClinicalTrials.gov identifier NCT03250299

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/eb41a76a-f233-4921-853c-82f69ffbd5c1

(END) Dow Jones Newswires

January 06, 2022 01:15 ET (06:15 GMT)